S&P 500   3,465.39 (+0.34%)
DOW   28,335.57 (-0.10%)
QQQ   284.74 (+0.20%)
AAPL   115.04 (-0.61%)
MSFT   216.23 (+0.62%)
FB   284.79 (+2.40%)
GOOGL   1,632.98 (+1.64%)
AMZN   3,204.40 (+0.88%)
TSLA   420.63 (-1.21%)
NVDA   543.61 (+1.72%)
BABA   309.92 (+1.19%)
CGC   19.73 (-2.81%)
GE   7.63 (-1.17%)
MU   52.85 (-2.81%)
AMD   81.96 (+3.20%)
T   27.82 (-1.63%)
F   8.16 (-0.61%)
ACB   4.68 (-3.51%)
GILD   60.79 (+0.20%)
NFLX   488.28 (+0.63%)
BA   167.36 (-1.01%)
NIO   27.16 (-0.80%)
DIS   128.35 (+0.62%)
S&P 500   3,465.39 (+0.34%)
DOW   28,335.57 (-0.10%)
QQQ   284.74 (+0.20%)
AAPL   115.04 (-0.61%)
MSFT   216.23 (+0.62%)
FB   284.79 (+2.40%)
GOOGL   1,632.98 (+1.64%)
AMZN   3,204.40 (+0.88%)
TSLA   420.63 (-1.21%)
NVDA   543.61 (+1.72%)
BABA   309.92 (+1.19%)
CGC   19.73 (-2.81%)
GE   7.63 (-1.17%)
MU   52.85 (-2.81%)
AMD   81.96 (+3.20%)
T   27.82 (-1.63%)
F   8.16 (-0.61%)
ACB   4.68 (-3.51%)
GILD   60.79 (+0.20%)
NFLX   488.28 (+0.63%)
BA   167.36 (-1.01%)
NIO   27.16 (-0.80%)
DIS   128.35 (+0.62%)
S&P 500   3,465.39 (+0.34%)
DOW   28,335.57 (-0.10%)
QQQ   284.74 (+0.20%)
AAPL   115.04 (-0.61%)
MSFT   216.23 (+0.62%)
FB   284.79 (+2.40%)
GOOGL   1,632.98 (+1.64%)
AMZN   3,204.40 (+0.88%)
TSLA   420.63 (-1.21%)
NVDA   543.61 (+1.72%)
BABA   309.92 (+1.19%)
CGC   19.73 (-2.81%)
GE   7.63 (-1.17%)
MU   52.85 (-2.81%)
AMD   81.96 (+3.20%)
T   27.82 (-1.63%)
F   8.16 (-0.61%)
ACB   4.68 (-3.51%)
GILD   60.79 (+0.20%)
NFLX   488.28 (+0.63%)
BA   167.36 (-1.01%)
NIO   27.16 (-0.80%)
DIS   128.35 (+0.62%)
S&P 500   3,465.39 (+0.34%)
DOW   28,335.57 (-0.10%)
QQQ   284.74 (+0.20%)
AAPL   115.04 (-0.61%)
MSFT   216.23 (+0.62%)
FB   284.79 (+2.40%)
GOOGL   1,632.98 (+1.64%)
AMZN   3,204.40 (+0.88%)
TSLA   420.63 (-1.21%)
NVDA   543.61 (+1.72%)
BABA   309.92 (+1.19%)
CGC   19.73 (-2.81%)
GE   7.63 (-1.17%)
MU   52.85 (-2.81%)
AMD   81.96 (+3.20%)
T   27.82 (-1.63%)
F   8.16 (-0.61%)
ACB   4.68 (-3.51%)
GILD   60.79 (+0.20%)
NFLX   488.28 (+0.63%)
BA   167.36 (-1.01%)
NIO   27.16 (-0.80%)
DIS   128.35 (+0.62%)
Log in
NASDAQ:OSMT

Osmotica Pharmaceuticals Stock Forecast, Price & News

$5.94
+0.07 (+1.19 %)
(As of 10/23/2020 03:59 PM ET)
Add
Compare
Today's Range
$5.79
Now: $5.94▼
$5.98
50-Day Range
$4.82
MA: $5.51▼
$6.29
52-Week Range
$2.81
Now: $5.94▼
$9.67
Volume4,418 shs
Average Volume401,270 shs
Market Capitalization$306.03 million
P/E RatioN/A
Dividend YieldN/A
Beta3.27
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER for treating Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone for muscle spasms; ConZip to treat pain; and Ontinua ER for treating opioid withdrawal symptoms. It also provides women's health products, including Divigel for menopause, as well as OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods; and RVL-1201 for treating Blepharoptos. In addition, the company's non-promoted approved products comprise Methylphenidate ER for ADHD; Venlafaxine ER tablets to treat major depressive disorder and social anxiety disorder; Hydromorphone ER for treating; Nifedipine ER for hypertension; Sodium Benzoate/Sodium Phenylacetate to treat hyperammonemia; Oxybutynin ER for overactive bladder; and prescription prenatal vitamins for treating nutritional requirements during pregnancy, as well as Osmodex ANDAs and other ANDAs for various treatments. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.
Read More

Beat the Market (BTM) Rank™

Analyst Opinion: 3.4Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.10 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OSMT
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.osmotica.com
Phone908-809-1300
Employees466

Debt

Debt-to-Equity Ratio2.05
Current Ratio3.17
Quick Ratio2.83

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$240.03 million
Price / Sales1.27
Cash Flow$6.83 per share
Price / Cash Flow0.87
Book Value$2.23 per share
Price / Book2.66

Profitability

EPS (Most Recent Fiscal Year)$0.25
Net Income$-270,900,000.00
Net Margins-73.47%
Return on Equity-15.61%
Return on Assets-4.38%

Miscellaneous

Outstanding Shares51,520,000
Market Cap$306.03 million
Next Earnings Date11/12/2020 (Estimated)
OptionableNot Optionable
$5.94
+0.07 (+1.19 %)
(As of 10/23/2020 03:59 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive OSMT News and Ratings via Email

Sign-up to receive the latest news and ratings for OSMT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Osmotica Pharmaceuticals (NASDAQ:OSMT) Frequently Asked Questions

How has Osmotica Pharmaceuticals' stock been impacted by Coronavirus?

Osmotica Pharmaceuticals' stock was trading at $5.06 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, OSMT stock has increased by 17.4% and is now trading at $5.94.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Osmotica Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Osmotica Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Osmotica Pharmaceuticals.

When is Osmotica Pharmaceuticals' next earnings date?

Osmotica Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for Osmotica Pharmaceuticals.

How were Osmotica Pharmaceuticals' earnings last quarter?

Osmotica Pharmaceuticals PLC (NASDAQ:OSMT) posted its quarterly earnings results on Tuesday, August, 11th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by $0.06. The firm had revenue of $37.53 million for the quarter, compared to analyst estimates of $38.50 million. Osmotica Pharmaceuticals had a negative return on equity of 15.61% and a negative net margin of 73.47%.
View Osmotica Pharmaceuticals' earnings history.

What price target have analysts set for OSMT?

4 analysts have issued twelve-month target prices for Osmotica Pharmaceuticals' stock. Their forecasts range from $4.00 to $12.00. On average, they expect Osmotica Pharmaceuticals' stock price to reach $9.25 in the next year. This suggests a possible upside of 55.7% from the stock's current price.
View analysts' price targets for Osmotica Pharmaceuticals.

Are investors shorting Osmotica Pharmaceuticals?

Osmotica Pharmaceuticals saw a increase in short interest in September. As of September 15th, there was short interest totaling 1,740,000 shares, an increase of 127.2% from the August 31st total of 765,900 shares. Based on an average daily volume of 588,000 shares, the short-interest ratio is presently 3.0 days. Approximately 11.1% of the company's stock are sold short.
View Osmotica Pharmaceuticals' Short Interest.

Who are some of Osmotica Pharmaceuticals' key competitors?

Some companies that are related to Osmotica Pharmaceuticals include Zogenix (ZGNX), Arcturus Therapeutics (ARCT), Mersana Therapeutics (MRSN), Phathom Pharmaceuticals (PHAT), Cytokinetics (CYTK), Generation Bio (GBIO), Constellation Pharmaceuticals (CNST), Applied Molecular Transport (AMTI), Nabriva Therapeutics (NBRV), Karyopharm Therapeutics (KPTI), NGM Biopharmaceuticals (NGM), Keros Therapeutics (KROS), Retrophin (RTRX), Intercept Pharmaceuticals (ICPT) and Rhythm Pharmaceuticals (RYTM).
View all competitors.

What other stocks do shareholders of Osmotica Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Osmotica Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), AbbVie (ABBV), AT&T (T), Canopy Growth (CGC), Idera Pharmaceuticals (IDRA), Opko Health (OPK), SCYNEXIS (SCYX), Zynerba Pharmaceuticals (ZYNE) and AstraZeneca (AZN).

Who are Osmotica Pharmaceuticals' key executives?

Osmotica Pharmaceuticals' management team includes the following people:
  • Mr. Brian A. Markison, Chairman, Pres & CEO (Age 60)
  • Mr. Andrew J. Einhorn, Chief Financial Officer (Age 59)
  • Dr. Tina Marie deVries, Exec. VP of R&D (Age 58)
  • Mr. James D. Schaub, Exec. VP & COO (Age 37)
  • Mr. Christopher A. Klein, Gen. Counsel & Sec. (Age 55)

When did Osmotica Pharmaceuticals IPO?

(OSMT) raised $58 million in an initial public offering on Thursday, October 18th 2018. The company issued 8,300,000 shares at a price of $7.00 per share. Jefferies, Barclays, RBC Capital MarketsWells and Fargo Securities served as the underwriters for the IPO.

What is Osmotica Pharmaceuticals' stock symbol?

Osmotica Pharmaceuticals trades on the NASDAQ under the ticker symbol "OSMT."

How do I buy shares of Osmotica Pharmaceuticals?

Shares of OSMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Osmotica Pharmaceuticals' stock price today?

One share of OSMT stock can currently be purchased for approximately $5.94.

How big of a company is Osmotica Pharmaceuticals?

Osmotica Pharmaceuticals has a market capitalization of $306.03 million and generates $240.03 million in revenue each year. The company earns $-270,900,000.00 in net income (profit) each year or $0.25 on an earnings per share basis. Osmotica Pharmaceuticals employs 466 workers across the globe.

What is Osmotica Pharmaceuticals' official website?

The official website for Osmotica Pharmaceuticals is www.osmotica.com.

How can I contact Osmotica Pharmaceuticals?

Osmotica Pharmaceuticals' mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The company can be reached via phone at 908-809-1300 or via email at [email protected]

This page was last updated on 10/23/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.